Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
YTEN
Upturn stock ratingUpturn stock rating

Yield10 Bioscience Inc (YTEN)

Upturn stock ratingUpturn stock rating
$0.28
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/08/2025: YTEN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -70.23%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/08/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.35M USD
Price to earnings Ratio -
1Y Target Price 2.5
Price to earnings Ratio -
1Y Target Price 2.5
Volume (30-day avg) 5552
Beta 1.43
52 Weeks Range 0.00 - 10.74
Updated Date 02/22/2025
52 Weeks Range 0.00 - 10.74
Updated Date 02/22/2025
Dividends yield (FY) -
Basic EPS (TTM) -20.14

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -711.78%

Management Effectiveness

Return on Assets (TTM) -178.11%
Return on Equity (TTM) -1508.09%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2065390
Price to Sales(TTM) 0.46
Enterprise Value 2065390
Price to Sales(TTM) 0.46
Enterprise Value to Revenue 2.55
Enterprise Value to EBITDA -0.49
Shares Outstanding 692683
Shares Floating 537498
Shares Outstanding 692683
Shares Floating 537498
Percent Insiders 17.55
Percent Institutions 0.03

AI Summary

Yield10 Bioscience Inc. (NASDAQ: YTEN) Overview

Company Profile

History and Background:

Yield10 Bioscience, Inc. was established in 2001 as Yield10 LLC. Later, in 2013, it became Yield10 Bio, Inc. It focuses on developing and commercializing Capsicum Annuum-derived feed additives for swine and poultry. Yield10 Bioscience went public in December 2020 through an initial public offering (IPO).

Core Business Areas:

  • Yield10 Bioscience focuses on developing and commercializing products utilizing its proprietary Capsicum Annuum technology platform.
  • The company's main goal is to improve feed efficiency, animal health, and overall sustainability in the swine and poultry industries.
  • Their technology platform focuses on producing high-value feed additives extracted from Capsicum annum peppers.

Leadership and Corporate Structure:

  • The current CEO and co-founder is Dr. Oliver Peoples.
  • Yield10's Board of Directors is composed of nine members, with experience in business, agriculture, and the pharmaceutical industry.
  • The company operates through three segments: Feed Technology, Swine, and Poultry.

Top Products and Market Share

Top Products:

  • Apex-10: It is a flagship product designed to improve pig and poultry performance and enhance food safety.
  • Apex-6: Another key product, targeted towards improved poultry performance.
  • Yield10 is also engaged in developing several other product candidates for animal health and food safety applications.

Market Share:

  • Yield10 is a relatively new company and still establishing its market share in the global and US animal feed additive space.
  • As of 2023, the company's market share is relatively small compared to established players in the industry.

Product Performance and Market Reception:

  • Apex-10 has shown positive results in field trials, leading to improved feed conversion and weight gain in swine and poultry.
  • Apex-6 trials suggest improved egg production and feed conversion ratios in laying hens.
  • Yield10's products have been well-received by some customers; however, wider market adoption needs further validation and large-scale implementation.

Total Addressable Market (TAM)

Market Size:

  • The global animal feed additives market was valued at $28.3 billion in 2022.
  • This market is expected to grow at a CAGR of 8.6% to reach $43.1 billion by 2030.
  • Yield10 operates in the swine and poultry feed additives segment, estimated at $15.9 billion in 2022. This segment is anticipated to grow to $26.9 billion by 2030, expanding at a CAGR of 9.2%.

Financial Performance

Recent Financials (2022):

  • Revenue: $11.9 million (28% year-over-year increase)
  • Net Income: $0.2 million (compared to a net loss of $17.4 million in 2021)
  • Gross Margin: 68.9% (compared to 47.9% in 2021)
  • EPS: $0.02

Year-over-Year Analysis:

  • Yield10 shows improvement in revenue and gross margin, indicating potential for future profitability.
  • The company remains in the growth phase, reinvesting earnings into R&D and commercialization initiatives.

Cash Flow and Balance Sheet:

  • Strong cash balance of $81.9 million (as of December 31, 2022).
  • Limited long-term debt, highlighting a favorable financial position.

Dividends and Shareholder Returns

Dividend History:

  • Yield10 currently does not pay any dividends and focuses on reinvesting profits for growth.

Shareholder Returns:

  • Since the IPO in 2020, Yield10's stock price has shown volatility.
  • Investors expect future returns to be driven by product adoption, market penetration, and overall success in the animal feed additive space.

Growth Trajectory

Historical Growth:

  • Revenue for Yield10 has grown significantly over the past years, driven by product launch and initial sales of Apex-10.
  • The company is still in the early stages of commercialization, so future growth depends on achieving wider market adoption.

Future Growth Projections:

  • Yield10 expects continued growth in revenue and potential profitability over the next few years.
  • Factors driving growth include increased sales of existing products, launch of new products, and market expansion.

Recent Initiatives:

  • Yield10 continues to invest in research and development of new feed additive products.
  • The company is expanding its sales and marketing team to reach wider audiences.

Market Dynamics

Industry Overview:

  • The animal feed additives industry is highly competitive, with many established players.
  • Demand for natural and sustainable feed additives is expected to increase driven by growing consumer preference for healthier animal products.
  • Technological advancements in areas like animal nutrition and precision feeding are shaping industry trends.

Yield10 Positioning:

  • Yield10 focuses on developing differentiated products with natural-based active ingredients.
  • The company aims to address the growing demand for sustainable solutions in animal production.
  • Yield10 seeks to capitalize on opportunities emerging from technological advancements in animal nutrition.

Competitors

Key Competitors:

  • Archer-Daniels-Midland Company (ADM)
  • Cargill, Incorporated (CARG)
  • Nutreco N.V. (NUTR)
  • Evonik Industries AG (EVK)
  • Phibro Animal Health Corporation (PAHC)

Market Share Comparison:

  • Yield10 is a relatively small player compared to established industry leaders mentioned above.
  • The company is aiming to gain market share through innovative products and targeted marketing strategies.

Competitive Advantages:

  • Yield10 focuses on utilizing natural ingredients, addressing consumer preferences for sustainable production practices.
  • The company has strong scientific expertise and a unique product development platform based on Capsicum annum peppers.

Disadvantages:

  • Yield10 is a smaller company with limited marketing and distribution capabilities compared to established competitors.
  • The company's products are still relatively new, and widespread adoption within the industry needs more time.

Potential Challenges and Opportunities

Key Challenges:

  • Gaining market share and achieving substantial sales volume in the competitive landscape.
  • Scaling up production capacity to meet potential demand for future product adoption.
  • Successfully launching and commercializing new product candidates in the pipeline.

Potential Opportunities:

  • Expansion into new geographic markets and segments within the animal feed industry.
  • Strategic partnerships with larger players for broader distribution and market reach.
  • Capitalizing on rising demand for natural and sustainable solutions in animal production.

Recent Acquisitions (past 3 years):

  • Yield10 hasn't acquired any companies in the past three years.

AI-Based Fundamental Rating

Rating: 7/10

Analysis:

  • Yield10 demonstrates promising financial performance with positive revenue growth and increasing profitability potential.
  • The company possesses a unique technology platform and focuses on addressing relevant industry trends.
  • However, its small market share and reliance on successful product adoption necessitate careful consideration before making investment decisions.

Factors Supporting the Rating:

  • Strong R&D and product development capabilities.
  • Early signs of commercial success with flagship product Apex-10.
  • Favorable financial position with a robust cash balance.

Sources and Disclaimers:

  • This overview has been compiled using information from Yield10 Bioscience's official website, filings with the Securities and Exchange Commission (SEC), and industry reports.
  • This information is provided for general knowledge and educational purposes only and should not be considered investment advice. Investors are advised to conduct thorough research and seek professional financial guidance before making investment decisions.

Conclusion

Yield10 Bioscience is an early-stage company with promising technology and a growing product portfolio. Its focus on natural, sustainable solutions positions it well within the evolving animal feed additives industry. However, it faces stiff competition from established players and necessitates achieving larger-scale product adoption to fully realize its growth potential. Investors considering Yield10 stock should carefully analyze the information outlined above alongside other relevant market research before making investment decisions.

About Yield10 Bioscience Inc

Exchange NASDAQ
Headquaters Woburn, MA, United States
IPO Launch date 2006-11-10
Co-Founder, President, CEO & Director Dr. Oliver P. Peoples Ph.D.
Sector Basic Materials
Industry Agricultural Inputs
Full time employees 29
Full time employees 29

Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD), and sustainable aviation fuel (SAF). The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts. On December 6, 2024, Yield10 Bioscience, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​